ライフサイエンスコーパス: divalproex

1 d event compared with placebo and lithium or divalproex.

2 cision the magnitude of benefit for adjuvant divalproex.

3 ment with lithium than during treatment with divalproex.

4 eport a 47-week comparison of olanzapine and divalproex.

5 hile more cases of nausea were reported with divalproex.

6 both phases, 12 has superior response taking divalproex.

7 se to placebo but was worse than response to divalproex.

8 or response to lithium or placebo but not to divalproex.

9 ponse to lithium and with better response to divalproex.

10 e, and is associated with better response to divalproex.

11 Attrition rates were similar for lithium and divalproex (14% and 18% at week 3 and 51% and 44% at wee

12 d flexibly dosed olanzapine (5-20 mg/day) to divalproex (500-2500 mg/day in divided doses) for the tr

13 d flexibly dosed olanzapine (5-20 mg/day) to divalproex (500-2500 mg/day) for manic or mixed episodes

14 ly shorter for olanzapine, 14 days, than for divalproex, 62 days.

15 ipolar disorder with mania were treated with divalproex, 750 mg/day for 2 days and then 1,000 mg/day

16 on; the evidence for anticonvulsants such as divalproex and lamotrigine is less robust and there is m

17 e who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol.

18 dose escalation design, the monotherapy with divalproex, and the control of variables that is possibl

19 rovement was greater for olanzapine than for divalproex, but rates of bipolar relapse did not differ.

20 nts stabilized on quetiapine plus lithium or divalproex, continued treatment was associated with a si

21 sodes, however, the responses to lithium and divalproex did not differ and were better than the respo

22 The present study examined the ability of divalproex (DVX), which is chemically related to valproi

23 resent study was to evaluate the efficacy of divalproex for reducing aggressive behavior among childr

24 The effects of olanzapine and divalproex for the treatment of mania were compared in a

25 e or placebo, in combination with lithium or divalproex, for up to 104 weeks.

26 The divalproex group did not differ significantly from the p

27 differ significantly between the lithium and divalproex groups (79% and 73%, respectively).

28 oportions of participants in the lithium and divalproex groups achieved target concentrations (57% an

29 Patients treated with divalproex had better outcomes than those treated with p

30 bility and efficacy of lithium carbonate and divalproex in 224 inpatients and outpatients age 60 or o

31 dose of the extended-release preparation of divalproex in an open 6-week trial.

32 acy and safety of quetiapine plus lithium or divalproex in the prevention of recurrent mood events in

33 timized stimulant treatment, the addition of divalproex increases the likelihood that aggression will

34 replicates open-label findings showing that divalproex is an efficacious treatment for explosive tem

35 This study compared the efficacy of divalproex, lithium, and placebo as prophylactic therapy

36 ere randomized to maintenance treatment with divalproex, lithium, or placebo in a 2:1:1 ratio.

37 icacy in acute mania is similar, lithium and divalproex may be most effective in clinically and biolo

38 proportion of children randomly assigned to divalproex met remission criteria (eight out of 14 [57%]

39 pine (N=125) and 10.4 for those treated with divalproex (N=123).

40 For divalproex, nausea was more frequently observed.

41 Use of extended-release divalproex once a day was as well tolerated as the stand

42 gned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 we

43 before randomization, except for open-label divalproex or lithium, which were gradually tapered over

44 order and the antimanic response to lithium, divalproex, or placebo.

45 lly stable while taking the standard form of divalproex participated in the study.

46 vent agitation and psychosis with the use of divalproex sodium (valproate).

47 Divalproex sodium alone (8-week trial) is not an effecti

48 manic symptoms and to discern the effect of divalproex sodium on ADHD was followed by a 4-week rando

49 An 8-week open-label trial of divalproex sodium to control manic symptoms and to disce

50 With divalproex sodium, 32 subjects achieved > or =50% reduct

51 te manic episodes were randomized to receive divalproex sodium, lithium carbonate, or placebo (ratio,

52 in the crossover trial continued to receive divalproex sodium.

53 ter their manic symptoms are stabilized with divalproex sodium.

54 e score > or =14 entered open treatment with divalproex sodium.

55 s had been stabilized through treatment with divalproex sodium.

56 xtended-release and standard preparations of divalproex sodium.

57 o improve while receiving the anticonvulsant divalproex sodium.

58 xible, divided doses) with either lithium or divalproex (target serum concentrations 0.5-1.2 meq/lite

59 get serum concentration, 0.80-0.99 mEq/L) or divalproex (target serum valproate concentration, 80-99

60 ted rates were greater during treatment with divalproex than during treatment with lithium for emerge

61 [CI], 1.1-6.3; P =.03) during treatment with divalproex than during treatment with lithium.

62 examined suicide risk during treatment with divalproex, the most commonly prescribed mood-stabilizin

63 ating Scale < or = 12), compared to 34.1% of divalproex-treated patients.

64 ia Rating Scale score), compared to 42.3% of divalproex-treated patients; 47.2% of olanzapine-treated

65 They received 6 weeks of divalproex treatment and 6 weeks of placebo by random as

66 ee randomized, placebo-controlled studies of divalproex treatment for acute mania was performed to te

67 rotocol-defined remission, compared with the divalproex treatment group.

68 Adverse experiences characteristic of divalproex treatment were disproportionately associated

69 reatment was 2.5 kg, compared to 0.9 kg with divalproex treatment.

70 Divalproex was generally well tolerated.

71 Divalproex was superior to lithium in longer duration of

72 Divalproex was superior to placebo in terms of lower rat

73 Both lithium and divalproex were adequately tolerated and efficacious; li

74 h alanine aminotransferase levels; those for divalproex were nausea and nervousness.

75 Acutely manic patients treated with divalproex who have valproate serum levels between 45 an

76 The authors hypothesized that divalproex would be better tolerated and more efficaciou

77 ase 1, eight of 10 subjects had responded to divalproex; zero of 10 had responded to placebo.